Indications
Cardiovascular and Metabolic Disorders

Stage of Development
Preclinical studies



Overview
Lexicon is developing monoclonal antibodies against LG843 as a potential treatment for cardiovascular and metabolic disorders such as dyslipidemia, metabolic syndrome, and hypertriglyceridemia.

Key Target
LG843 is a secreted protein.  As part of the Genome5000^TM program, Lexicon scientists found that mice lacking this protein exhibited substantially reduced triglyceride and cholesterol levels, with no adverse effects observed.

Preclinical Status
In preclinical research, LG843 antibodies substantially reduced triglyceride and cholesterol levels.  Lexicon is conducting ongoing preclinical pharmacology and antibody optimization studies, and is evaluating multiple clinical approaches for an antibody drug candidate targeting LG843.